Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q4 EPS of ($0.45), $0.14 worse than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.